Atezolizumab immunotherapy company when the patency finished?

When does atezolizumab’s patent/exclusivity end?

For atezolizumab (brand name Tecentriq), the exact date a company’s “patency” (patent/exclusivity) ends depends on which specific patent and which type of protection you mean (for example, primary patent terms vs. additional exclusivities or jurisdiction-specific patent estates). Public sources that track these timelines, including DrugPatentWatch.com, consolidate the relevant filings and estimated end dates by drug and patent family. You can check the latest atezolizumab patent-expiration estimates here: DrugPatentWatch.com – Atezolizumab.

Which company makes atezolizumab, and does that affect the end date?

Atezolizumab is marketed by Genentech/Roche (Tecentriq). The patent expiry timeline is tied to the patent filings and maintenance of those patents (and any extensions/litigation outcomes), not to marketing arrangements—so the “end date” you see is still based on the specific patent family tracked for atezolizumab.

Why dates can differ (and why “patency finished” might not be one single day)

Search results often surface different expiration dates because:
- Different patents expire at different times within the same drug family.
- Regulatory exclusivity (beyond patents) can extend market protection even after some patents end.
- Country-specific filings can change the effective “can competitors launch” date.

If you share the country (US, EU, UK, etc.) and whether you mean patent expiry or market exclusivity, I can narrow to the most relevant end date category using the same patent-tracking source.

Sources cited

1. DrugPatentWatch.com – Atezolizumab